Log in

NASDAQ:JNCE - Jounce Therapeutics Stock Price, Forecast & News

$5.76
+0.48 (+9.09 %)
(As of 02/25/2020 07:00 AM ET)
Today's Range
$4.85
Now: $5.76
$5.81
50-Day Range
$5.28
MA: $6.56
$7.97
52-Week Range
$2.79
Now: $5.76
$10.00
Volume812,974 shs
Average Volume472,740 shs
Market Capitalization$191.40 million
P/E Ratio2.56
Dividend YieldN/A
Beta4.05
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.20 million
Book Value$3.18 per share

Profitability

Net Income$-27,380,000.00

Miscellaneous

Employees115
Market Cap$191.40 million
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.


Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) issued its quarterly earnings data on Thursday, November, 7th. The company reported $2.90 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.24 by $0.66. The business earned $119.45 million during the quarter, compared to analysts' expectations of $99.97 million. Jounce Therapeutics had a net margin of 46.11% and a return on equity of 64.54%. View Jounce Therapeutics' Earnings History.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Jounce Therapeutics.

How can I listen to Jounce Therapeutics' earnings call?

Jounce Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What is the consensus analysts' recommendation for Jounce Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Has Jounce Therapeutics been receiving favorable news coverage?

News stories about JNCE stock have been trending neutral on Tuesday, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jounce Therapeutics earned a news impact score of 0.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Jounce Therapeutics.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,200,000 shares, an increase of 25.0% from the January 15th total of 1,760,000 shares. Based on an average daily volume of 718,300 shares, the short-interest ratio is presently 3.1 days. Approximately 14.1% of the company's stock are sold short. View Jounce Therapeutics' Current Options Chain.

Who are some of Jounce Therapeutics' key competitors?

What other stocks do shareholders of Jounce Therapeutics own?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 60)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
  • Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (3.73%), Acadian Asset Management LLC (2.04%), Marshall Wace LLP (1.43%), Renaissance Technologies LLC (1.23%), State Street Corp (1.23%) and Geode Capital Management LLC (0.78%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

Which institutional investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Prudential Financial Inc., Bank of America Corp DE, Goldman Sachs Group Inc., State Street Corp, Bailard Inc., Meeder Asset Management Inc. and Tower Research Capital LLC TRC . Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.

Which institutional investors are buying Jounce Therapeutics stock?

JNCE stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Renaissance Technologies LLC, Acadian Asset Management LLC, Point72 Asset Management L.P., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc. and Oxford Asset Management LLP. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $5.76.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $191.40 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is http://www.jouncetx.com/.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  213 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel